Ideas
Overreaction to lower deal and royalty terms.
Alteogen plunged after two disappointments: its GSK/Tesaro license for Tostarima subcutaneous development and commercialization was only about KRW 420bn versus market expectations of at least KRW 1tn based on the prior KRW 1.9tn deal, and a disclosed Keytruda SC royalty rate of 2% was at the low end of the 2-5% analyst range, cutting expected annual royalties to roughly KRW 40bn versus up to KRW 1.25tn at 5%. However, the GSK deal also validates Alteogen's technology because GSK had previously partnered with rival Halozyme, and the contract is not small versus the earlier Daiichi Sankyo deal; the selloff was amplified by a weak market and may be overdone, though earnings estimates need to reset.
Japanese yields threaten global carry trade.
Japan's 40-year government bond yield broke 4.2%, approaching US Treasury levels, as expected fiscal expansion and consumption-tax-cut pledges ahead of the February 8 election raised concerns about Japan's fiscal path. Because Japanese investors hold about USD 1.2tn of US Treasuries, higher JGB yields could prompt them to repatriate funds from US Treasuries into JGBs, reviving yen-carry unwind fears and causing a domino rise in US, European, and Korean bond yields. Lee calls this the biggest current risk for global fund flows and for rate-sensitive growth assets.
Rising yields pressure rate-sensitive KOSDAQ.
KOSDAQ is relatively more vulnerable to rising long-term bond yields because it is dominated by long-duration growth sectors such as biotech and robotics. Lee notes KOSDAQ fell more than 4% while KOSPI held up, showing that rate-driven pressure is concentrating in KOSDAQ.
Hyundai can rival Tesla in robotics.
KB Securities raised Hyundai Motor's target price from KRW 330,000 to KRW 800,000, arguing it is the only robotics company that can counter Tesla. Lee agrees: after seeing Atlas, he sees Hyundai as a credible Tesla rival in robotics. The report drove Hyundai up more than 10% above KRW 500,000 and led the Korean robot complex.
Non-Hyundai robot stocks look overbought.
Outside Hyundai, the broad Korean robot rally looks overbought and indiscriminate, with many stocks rising on theme alone and some moves hard to justify. Lee advises investors to separate true robotics winners from speculative names.
ETF inflows strongly cushion Korean equities.
ETF inflows into Korean equities are extremely strong, and because ETFs must deploy incoming cash, institutional buying is effectively retail buying through ETFs. This powerful liquidity is cushioning the market's correction, even as individuals sell KOSPI and rotate some funds to KOSDAQ.
US LNG projects lift Korean suppliers.
Trump renewed mention of Alaska LNG and said Korean and Japanese funds could help finance it; Lee expects US-origin LNG projects, including Alaska LNG, to be active this year. This should support order expectations for Korean shipbuilders and has already driven sharp gains in Korean LNG-related steel pipe, gas pipe, and valve suppliers such as Daedong Steel, HiSteel, and Hwaseong Valve.
Biotech suffers as rates hit growth.
Biotech was the hardest-hit area in the rate-driven selloff, with obesity-treatment and dementia-treatment stocks broadly falling. Lee treats this as evidence that rising long-term yields are pressuring high-duration healthcare/growth names in Korea.
US 10-year breakout opens further yield rise.
US 10-year and 20-year Treasury yields surged, and the 10-year yield broke the important 4.2% line, which opens room for a further rise in long-term US yields. This is part of the same Trump/Greenland and fiscal-risk backdrop, and until US yields stabilize, they remain a key risk for global equities and growth stocks.
KOSPI correction likely, 20-day average support.
KOSPI has run up without a real correction. If uncertainty persists, the 20-day moving average, likely near 4,600, should be the key support, implying only about a 5% correction from roughly 4,900; even a 10% correction would be healthy in an uptrend. The trend is not broken, so it is not a sell signal, but investors should allow for further index correction.
Korean autos may benefit from EU tariffs.
If Trump imposes additional tariffs on European countries, autos are the most directly Korea-linked affected item; European automakers would be relatively disadvantaged while Korean and Japanese automakers become more competitive. Lee views this as a significant possibility if Trump acts, though it remains contingent on the trade conflict.
This 815 Money Talk (815머니톡) video, published January 21, 2026,
features Lee Dong-geun
discussing 196170.KQ, Japan 40-year government bonds, Korean government bonds, KOSDAQ, 005380.KS, Korean robotics stocks, Korean equity ETFs, Daedong Steel, 005670.KQ, Hwaseong Valve, Korean shipbuilders, XBI, Korean obesity drug stocks, Korean dementia treatment stocks, IEF, US20Y, EWY, Korean automakers, Japanese automakers.
11 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Dong-geun
· Tickers:
196170.KQ,
Japan 40-year government bonds,
Korean government bonds,
KOSDAQ,
005380.KS,
Korean robotics stocks,
Korean equity ETFs,
Daedong Steel,
005670.KQ,
Hwaseong Valve,
Korean shipbuilders,
XBI,
Korean obesity drug stocks,
Korean dementia treatment stocks,
IEF,
US20Y,
EWY,
Korean automakers,
Japanese automakers
